Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2011 Mar;89(3):348-50. doi: 10.1038/clpt.2010.310.

Pharmacogenomics: "noninferiority" is sufficient for initial implementation.

Author information

  • 1Department of Bioengineering, Stanford University, Stanford, California, USA. russ.altman@stanford.edu

Abstract

Recent clinical annotation of a whole-genome sequence suggests that pharmacogenomics (PGx) may be ready for clinical implementation now. This conclusion rests on the recognition that PGx has greatly mitigated risks as compared with using genomics for assessment of disease risk. Failure to recognize these differences can produce unrealistic cost-benefit scenarios and impractical standards of evidence. In many cases, pharmacogenetic tests need only reach reasonable expectations of noninferiority (compared with current prescribing practices) to merit use.

PMID:
21326263
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk